menu
    • menu
    [{"orgOrder":0,"company":"Genexine","sponsor":"Genexine","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"GX-19","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Genexine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Genexine \/ Genexine","highestDevelopmentStatusID":"1","companyTruncated":"Genexine \/ Genexine"},{"orgOrder":0,"company":"Genexine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"GX-19","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Genexine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Genexine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Genexine \/ Not Applicable"},{"orgOrder":0,"company":"Genexine","sponsor":"PT Kalbe Farma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"GX-19","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Genexine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Genexine \/ PT Kalbe Farma","highestDevelopmentStatusID":"4","companyTruncated":"Genexine \/ PT Kalbe Farma"},{"orgOrder":0,"company":"Genexine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"HyLeukin-7","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Genexine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Genexine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Genexine \/ Not Applicable"},{"orgOrder":0,"company":"Genexine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"GX-19","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Genexine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Genexine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genexine \/ Not Applicable"},{"orgOrder":0,"company":"Genexine","sponsor":"PharmaJet","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"GX-19","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Genexine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Genexine \/ Genexine","highestDevelopmentStatusID":"7","companyTruncated":"Genexine \/ Genexine"},{"orgOrder":0,"company":"Genexine","sponsor":"I-Mab Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Eftansomatropin","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Genexine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genexine \/ Genexine","highestDevelopmentStatusID":"8","companyTruncated":"Genexine \/ Genexine"},{"orgOrder":0,"company":"Genexine","sponsor":"NeoImmuneTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"IL-7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genexine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Genexine \/ NeoImmuneTech","highestDevelopmentStatusID":"7","companyTruncated":"Genexine \/ NeoImmuneTech"},{"orgOrder":0,"company":"Genexine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"GX-19","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Genexine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Genexine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genexine \/ Not Applicable"},{"orgOrder":0,"company":"Genexine","sponsor":"Kalbe Genexine Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Efineptakin alfa","moa":"IL-7","graph1":"Oncology","graph2":"Phase I","graph3":"Genexine","amount2":1.1000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.1000000000000001,"dosageForm":"Intramuscular Injection","sponsorNew":"Genexine \/ KGBio","highestDevelopmentStatusID":"6","companyTruncated":"Genexine \/ KGBio"},{"orgOrder":0,"company":"Genexine","sponsor":"Genexine","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"GX-19N","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Genexine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Genexine \/ Genexine","highestDevelopmentStatusID":"7","companyTruncated":"Genexine \/ Genexine"},{"orgOrder":0,"company":"Genexine","sponsor":"Hanmi Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"GX-19N","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Genexine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Genexine \/ Genexine","highestDevelopmentStatusID":"7","companyTruncated":"Genexine \/ Genexine"},{"orgOrder":0,"company":"Genexine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"IL-7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genexine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Genexine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genexine \/ Not Applicable"},{"orgOrder":0,"company":"Genexine","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"GX-188E","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Genexine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Genexine \/ MSD","highestDevelopmentStatusID":"8","companyTruncated":"Genexine \/ MSD"},{"orgOrder":0,"company":"Genexine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"GX-188E","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Genexine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Genexine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Genexine \/ Not Applicable"},{"orgOrder":0,"company":"Genexine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"GX-188E","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Genexine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Genexine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Genexine \/ Not Applicable"},{"orgOrder":0,"company":"Genexine","sponsor":"I-Mab Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Eftansomatropin Alfa","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Genexine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Genexine \/ I-Mab Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Genexine \/ I-Mab Biopharma"},{"orgOrder":0,"company":"Genexine","sponsor":"Kalbe Genexine Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Efepoetin Alfa","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Genexine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genexine \/ Kalbe Genexine Biologics","highestDevelopmentStatusID":"12","companyTruncated":"Genexine \/ Kalbe Genexine Biologics"},{"orgOrder":0,"company":"Genexine","sponsor":"EPD Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Large molecule","year":"2024","type":"Merger","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Genexine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Genexine \/ EPD Biotherapeutics","highestDevelopmentStatusID":"14","companyTruncated":"Genexine \/ EPD Biotherapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Genexine

    Menu

    Genexine

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Genexine

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Genexine

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Sponsor : EPD Biotherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Genexine Announces Merger with EPD Biotherapeutics to Strengthen Drug Development Pipeline

                            Details : Through this merger, Genexine will secured key talent with innovative technology that can lead the global market and innovative new drugs based on combining EPD Bio’s bioPROTAC technology.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            July 04, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Sponsor : EPD Biotherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Genexine

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Genexine

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Efepoetin Alfa

                            Therapeutic Area : Nephrology

                            Study Phase : Approved

                            Sponsor : Kalbe Genexine Biologics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Genexine and KGbio Received the First Market Approval for Novel Long-acting Erythropoietin, Efepoetin Alfa, fr...

                            Details : Efesa (efepoetin alfa) is a bio-better drug for CKD-induced anemia, developed based on hyFc®, Genexine's proprietary long-acting platform technology, which is investigated for the treatment of chronic kidney disease induced anemia in non-dialysis patien...

                            Brand Name : Efesa

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 23, 2023

                            Lead Product(s) : Efepoetin Alfa

                            Therapeutic Area : Nephrology

                            Highest Development Status : Approved

                            Sponsor : Kalbe Genexine Biologics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Genexine

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Genexine

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eftansomatropin Alfa

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Sponsor : I-Mab Biopharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Genexine’s long-acting growth hormone meets Phase 3 primary endpoint

                            Details : Genexine’s, GX-H9, a proprietary long-acting growth hormone shows positive topline results from phase 3 study for growth hormone deficiency, is being conducted in China with I-Mab.

                            Brand Name : GX-H9

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 30, 2023

                            Lead Product(s) : Eftansomatropin Alfa

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Sponsor : I-Mab Biopharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Genexine

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Genexine

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GX-188E,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Genexine Receives Fast Track Designation from Korean Health Authority (MFDS) for Its Promising DNA Vaccine for...

                            Details : GX-188E (tirvalimogene teraplasmid), a DNA vaccine encoding both E6 and E7 antigens of HPV types 16 and 18, which are responsible for about 70% of cervical cancer. It induces antigen-specific CD8 T cell responses by Flt3L fusion.

                            Brand Name : GX-188E

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            January 20, 2023

                            Lead Product(s) : GX-188E,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Genexine

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Genexine

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GX-188E,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Genexine to Present Final Phase 2 Clinical Data on Its Cervical Cancer Program Showing a 35.0% Overall Respons...

                            Details : GX-188E is a DNA vaccine that encodes the E6/E7 fusion protein of HPV subtypes 16 and 18. Drug induces immune cells to detect E6 and E7 proteins that exist in cervical cancer cells, inducing apoptosis of tumor cells without affecting healthy cells.

                            Brand Name : GX-188E

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            January 08, 2023

                            Lead Product(s) : GX-188E,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Genexine

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Genexine

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GX-188E,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : MSD Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Genexine Selected for Late-Breaking Oral Presentation of Phase 2 Study of GX-188E in Combination with KEYTRUDA...

                            Details : GX-188E is a DNA-based therapeutic vaccine that was discovered and is being developed by Genexine for the treatment of cervical cancer and squamous cell carcinoma of the head and neck.

                            Brand Name : GX-188E

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            August 25, 2022

                            Lead Product(s) : GX-188E,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : MSD Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Genexine

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Genexine

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Efineptakin Alfa,Pembrolizumab,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Genexine Reports Encouraging Top-line Results of the Phase 1b/2 Clinical Trial With GX-I7 (efineptakin alfa) i...

                            Details : The results indicated that GX-I7 (Efineptakin Alfa) in combination with pembrolizumab was safe and well tolerated and demonstrated promising early anti-tumor activity in patients with R/R metastatic TNBC.

                            Brand Name : GX-I7

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 07, 2022

                            Lead Product(s) : Efineptakin Alfa,Pembrolizumab,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Genexine

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Genexine

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GX-19N

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Recipient : Hanmi Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            S.Korea's Genexine Signs COVID-19 Vaccine Candidate Manufacturing Deal with Hanmi

                            Details : Genexine 's GX-19N COVID-19 vaccine candidate is a DNA based vaccine and showed no severe side effects. Hanmi will begin producing 10M doses of Genexine’s experimental COVID-19 vaccine with an aim to gradually ramp up production capacity to millions of...

                            Brand Name : GX-19N

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            May 18, 2021

                            Lead Product(s) : GX-19N

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Hanmi Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Genexine

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Genexine

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GX-19N

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Recipient : Institut Pasteur Korea

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Institut Pasteur Korea & Genexine Sign MOU for Global Clinical Trials for the COVID-19 Vaccine

                            Details : IPK and Genexine will join forces together to test the protective efficacy of the GX-19N in the regions such as South Africa, where variants mainly appear, utilizing the international collaboration network of Institut Pasteur Korea.

                            Brand Name : GX-19N

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            April 12, 2021

                            Lead Product(s) : GX-19N

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Institut Pasteur Korea

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Genexine

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Genexine

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Efineptakin alfa

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Kalbe Genexine Biologics

                            Deal Size : $1,100.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            KGBio and Genexine Signed Immuno-Oncology Drug License Agreement GX-17

                            Details : Through this licensing agreement, KGBio and Genexine aim to develop a and commercialize an immuno-oncology drug GX-I7 (Efineptakin Alpha), namely long-acting interleukin-7 which uses the Genexine hyFc technology platform.

                            Brand Name : GX-I7

                            Molecule Type : Large molecule

                            Upfront Cash : $27.0 million

                            February 18, 2021

                            Lead Product(s) : Efineptakin alfa

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Kalbe Genexine Biologics

                            Deal Size : $1,100.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth